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ABSTRACT 
Background: Critical limb ischemia (CLI) presented as a foot ulcer with or without 
gangrene requires the quick re-establishment of arterial blood supply. The recently 
introduced angiosome concept has offered a new perspective on the treatment of CLI.  The 
idea of angiosome-targeted (direct) revascularization⎯the restoration of blood flow 
directly to the angiosome affected by an ischemic wound—appeared among vascular 
surgeons.  
The concept has rised interest among vascular specialists as several studies supported the 
hypothesis of a better clinical outcome after direct revascularization. Despite the promising 
results, the feasibility of the concept in endovascular treatment has not been addressed, nor 
has a comparison of revascularization methods, endovascular versus open surgical, been 
investigated. Furthermore, the methodology is not consistent, and the definition of direct 
revascularization is unclear, especially if the wound spreads over several angiosomes. 
Therefore, clinical value of the hypothesis is yet to determined. 
Aim of the study: The aim of this study was to investigate the importance of the 
angiosome concept in the treatment of CLI with tissue loss (Rutherford 5,6). The main 
goals were to evaluate the feasibility of the concept in endovascular procedures; to 
compare the clinical outcomes of direct and indirect revascularization; and to obtain a 
consensus concerning the angiosome-targeted approach.   
Patients and methods: The study comprises patients referred for infrapopliteal 
revascularization, endovascular or open surgical, between 2008 and 2013. We analyzed 
patient’s records retrospectively, focusing on wound location, the feasibility of 
infrapopliteal direct revascularization, and differences in clinical outcome, with the main 
interest in wound healing and leg salvage. We also compared the clinical outcome of two 
existing definitions of angiosome-targeted revascularizations as they differ in 
revascularization approach of leasions located in forefoot and the heel.  Definition A 
accepts into the direct group if any of the affected angiosomes is revascularized, while 
Definition B accepts only revascularization of posterior tibal artery. 
Main Results:  For the feasibility of the angiosome concept in endovascular infrapopliteal 
revascularization, the wound was isolated to a single angiosome in only 24% of the cases, 
and 33% of the patients had only one infrapopliteal artery suitable for revascularization. 
The success rate of direct revascularization, however, was 75.9%.  
When comparing direct and indirect revascularization, the propensity score analysis 
yielded significantly better leg salvage (p=0.019) and a trend towards improved wound 
healing (p=0.058) for the direct approach, and when adjusted for revascularization method, 
direct bypass was associated with a significantly higher wound-healing rate than 
endovascular revascularization (HR 1.295, 95%CI 1.005–1.668).  
Among diabetic patients, the findings showed that direct bypass yielded significantly better 
wound healing than indirect PTA (p=0.001, HR 2.83, 95%CI 1.35–3.04), and, furthermore, 
indirect PTA was associated with the poorest leg salvage rate.  
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The analysis of the two different angiosome-targeted approaches revealed a significantly 
better feasibility of the conventional method (definition A) compared to definition B 
(p<0.05). Furthermore, the prognostic ability for better clinical outcome using definition A 
was confirmed by both the Cox proportional hazard analysis (p= 0.044 for wound healing, 
p= 0.047 for leg salvage) and the propensity score analysis (p= 0.037 for wound healing, 
p= 0.044 for leg salvage). 
Conclusion: The tissue lesion affects several angiosomes in the majority of the cases, and 
a consensus on the accurate definition of angiosome-targeted revascularization needs to be 
achieved to standardize the methodology of arterial selection. Despite the inconsistent 
methodology in the literature, our findings seem to suggest that observing the angiosome 
concept in the decision-making yields better clinical outcomes, especially in endovascular 
therapy. In bypass surgery, however, the concept seems to be of less value, and the artery 
with the best runoff should be selected as the outflow artery.  
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INTRODUCTION 
 
Critical limb ischemia (CLI) presented as a foot ulcer with or without gangrene is a serious 
impairment of a patient’s health status and requires a quick re-establishment of arterial 
blood supply. The incidence of CLI is expected to rise with the increasing proportion of 
the elderly population as well as prevalence of diabetes mellitus (DM) (Rothwell et al. 
2005, WHO, Armstrong et al. 2013), which are significant risk factors for the progression 
of asymptomatic peripheral artery disease or claudication into CLI (Norgren et al. 2007, 
Thiruvoipati et al. 2015). 
The direction of treatment, in terms of revascularization options, has changed dramatically, 
shifting towards an “endovascular first” strategy and decreasing the number of patients 
primarily referred for open surgical revascularization (Goodney et al. 2009). Irrespective of 
the revascularization method, the literature states that pulsatile flow to the correct region of 
the foot is necessary to heal ischemic tissue loss (Treiman et al. 2003, Hughes et al. 2004). 
Defining such a region for revascularization, however, remains under debate.  
The recently introduced angiosome concept has offered a new perspective on 
revascularization location. An angiosome was defined by Taylor et al. (1987) as a three-
dimensional block of tissue supplied and drained by specific, “angiosomal vessels.” In 
2006, Attinger et al. presented that the foot consist of 6 angiosome regions, each supplied 
by one of the crural arteries and its terminal branches. The concept of angiosome-targeted 
(direct) revascularization is based on this division, and direct revascularization (DR) refers 
to the selective revascularization of the specific artery feeding the angiosome that is 
affected by an ischemic ulcer (Varela et al. 2010, Söderström et al. 2013, Neville et al. 
2009, Azuma et al. 2012, Acín et al. 2014, Kret et al. 2014).  
Two meta-analyses, including a total of 15 studies, have reported better clinical outcomes 
in favor of direct revascularization, especially in patients with diabetes (Bosanquet et al.  
2014, Biancari and Juvonen 2014).  However, the feasibility of the concept has not been 
investigated, nor has there been a comparison between revascularization methods—
endovascular treatment versus open surgical. Furthermore, the methodology of DR is not 
consistent in the literature, and two different definitions of DR exist (Varela et al. 2010, 
Söderström et al.  2013, Alexandrescu et al. 2013). Therefore, we focused our interest on 
these issues in the present study.    
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 REWIEV OF THE LITERATURE 
Peripheral arterial disease 
1.1.1 Definition  
Peripheral arterial disease (PAD) is defined as a narrowing the lumen of peripheral 
arteries, with the exception of those supplying the brain and heart. The narrowing is caused 
by diffuse atherosclerosis—a systemic inflammatory disease leading to the development of 
an atherosclerotic plaque.  
The pathophysiology of atherosclerosis has been studied intensively over the past decade. 
It seems to be a degenerative inflammatory process of the vessel wall, starting with 
endothelial dysfunction and leading to an increased permeability to lipoproteins and other 
plasma constituents.  This causes the migration of leucocytes and monocytes-macrophages 
into the subendothelial space. The production of inflammatory mediators stimulates the 
proliferation of smooth muscles in the intima, forming a fibrous cap that weakens the 
mechanical stability of the plaque and separates the lipid-rich thrombogenic core from the 
lumen and circulating blood (Mitchell and Sidawy 2005).  
PAD can be determined with a simple non-invasive procedure by calculating the ankle-
brachial index (ABI), which has high sensitivity and specificity. An ABI value between 1–
1.4 is considered normal, while 0.9 or less indicates PAD. ABI values of 0.91–0.99 are 
considered borderline and values >1.4 indicate non-compressible arteries (Rooke et al. 
2011). 
   
1.1.2  Epidemiology 
The prevalence of PAD rises sharply with age—while PAD affects 12–14% of the general 
population, the figure rises to 20% at the age of ≥75 years (Crigui and Aboyans.  2015).  
The incidence of PAD in the male population is 1.7/1000 at the age of 40–54 years, 
1.5/1000 at the age of 55–64 years, and 17.8/1000 at the age of over 65 years. The annual 
incidence among women increases after menopause: 22.9/1000 at the age over 65 years 
(Hooi et al.  2001). Even though the male population has lower incidence rates, both the 
incidence and prevalence of symptoms in terms of intermittent claudication (IC) are twice 
as high among men compared to a women (Kannel and McGee. 1985, Meijer et al. 1998, 
and Murabito et al. 2002).  
A study by Allison et al. (2007) performed on a large American population showed that the 
prevalence also varies dramatically between ethnic groups. While approximately 20% of 
the non-Hispanic white population suffered from PAD at the age of 80 years, the rate for 
African Americans was twice as high.  
Globally, within one decade (2000-2010) the number of individuals with PAD increased 
by 28.7% in low-income and middle-income countries and by 13.1% in high-income 
countries (Fowkes et al. 2010). The prevalence is likely to increase even further in the 
future due to the growing number of older people with a prolonged life expectancy 
(WHO).  
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1.1.3 Risk factors 
Unlike the risk factors of coronary artery (CAD) and cerebrovascular disease (CVD), 
which have been studied extensively (Donelly and Yeung 2002), the amount of literature 
focusing only on PAD risk factors is limited. The reason is that the onset of PAD as 
defined by the ABI is asymptomatic in two thirds of patinets and, therefore, it is unlikely to 
be documented in the records of health care providers (Sigvant et al. 2007, McDermott et 
al 2000). However, five large epidemiological studies, similar in materials and methods, 
allow a reasonable comparison of the most common risk factors (Murabito et al. 2002 and 
1997, Newman et al. 1993, Meijer et al. 2000, and Allison et al. 2007). 
 
1.1.3.1 Smoking 
There is a significant, independent association between PAD and smoking. The association 
is even stronger than between smoking and CAD (Dormandy and Rutherford. 2000). 
Current smoking increases the probability of developing PAD 2–4-fold. A clear dose-
response relationship between smoking and the risk of PAD was observed (Fowkes et al. 
1992, Willigendael et al. 2004). Even the age at the onset of smoking showed a significant 
increase in risk when a person started smoking at an age of ≤16 years (Planas et al. 2002).  
Current smoking is the most important modifiable risk factor for symptomatic PAD and 
the development of critical limb ischemia, as smoking promotes endothelial dysfunction 
and alters lipid metabolism and coagulation (Lu and Creager 2004). Furthermore, smokers 
have a higher risk of peri- and postoperative complications in connection with both 
percutaneous interventions and open surgery (Shammas et al. 2007), which leads to an 
increased risk of amputation and mortality (Lassila and Lepäntalo. 1988, Galaria et al. 
2005). Even though the risk of PAD stays elevated even 20 years after smoking cessation 
(Joosten et al. 2012), quitting smoking slows down the progression of PAD and relieves 
the symptoms (Collison and Donelly 2006). Therefore, all patients should be informed of 
the consequences and encouraged to stop smoking. 
 
1.1.3.2  Diabetes mellitus 
Diabetes is one of the strong predictors of PAD and plays the main role in the progression 
of the disease, making these patients more prone to ischemic events with impaired 
functional status when compared to patients without diabetes (Thiruvoipati et al. 2015). 
Glucose intolerance is associated with a 20%–30% prevalence of abnormal ABI as 
opposed to the 7% in those with normal glucose tolerance (Beckman et al. 2002). The 
severity and duration of diabetes are predictors of both the incidence and extent of PAD, as 
each 1% increase in glycosylated hemoglobin (HbA1C) correlates with a 28% increase in 
incidence of the disease (Selvin et al. 2006, Jude et al. 2001).  
In Patients with diabetes the PAD affects mainly the infrapopliteal arteries, in addition 
diabetic patients experience a later onset of symptoms due to concomitant peripheral 
neuropathy (American Diabetes Association 2003). Nerve malfunction diminishes sensory 
feedback and minimizes pain perception. This leads to late reporting to the clinician; the 
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disease is usually already advanced, such as an ischemic ulcer or gangrene (Hirsch et al. 
2006, Setacci et al. 2009, Jude et al. 2001).  
Diabetic patients who develop critical limb ischemia, 30% will undergo major amputation, 
and the 6-month mortality rate among them is 20% (Dormandy and Rutherford. 2000). The 
increased severity of PAD may be explained by a different pathophysiology of 
atherosclerosis, as diabetes is multifactorial and includes inflammatory processes (Pradhan 
et al. 2001, Paneni et al. 2013 and Beckaman et al. 2013), derangements of various cell 
types within the vascular wall (Troidl and Schaper 2012, Suzuki 2001, Uemura 2001), the 
promotion of coagulation (Armstrong et al. 2013, Carr 2001), and the inhibition of 
fibrinolysis (Vinik et al. 2001). Such factors lead to higher susceptibility of the vessel to 
atherosclerosis as well as the instability of the plaque (Thiruvoipati et al. 2015).  
Globally, over 170 million people suffer from DM, and the number is projected to increase 
to 366 million by 2030 (Armstrong et al. 2014,Wild et al. 2004). Therefore, early 
administration of treatment, good follow-up and collaboration between different specialists 
are needed to improve the clinical outcome. 
 
1.1.3.3 Dyslipidemia 
The role of dyslipidemia in PAD is still not as clear as the role of smoking and diabetes 
mellitus (Reiner et al. 2011). Total cholesterol has been examined as a potential risk factor 
in several studies, and it was significantly associated with PAD in multivariable analysis in 
the majority of the studies (Newman et al. 1993, Bainton et al. 1994, Meijer 2000).  
Only one study reported a significant association between dyslipidemia and PAD when 
using univariate analysis (Murabito et al. 2002). On one hand, the Framingham study 
showed that a fasting total cholesterol level greater than 7 mmol/L was associated with 
twice as high an incidence of the progression from asymptomatic to symptomatic PAD 
(Kannel 1994). On the other hand, a study by Mowat et al. (1997) comparing patients with 
PAD to healthy controls suggested that the protective role of high-density lipoprotein 
(HDL) might play a more important role than the atherogenic effect of low-density 
lipoprotein (LDL). A few studies also found an association between an increased level of 
triglycerides and PAD. This may be due to the fact that abnormal levels of triglycerides are 
often present in DM and metabolic syndrome, which themselves are risk factors for PAD 
and its progression (Smith et al. 1996, Stalenhoef and de Graaf 2008).  
Treatment with statins reduces the incidence of PAD progression (Pedersen et al. 1998, 
Hearth Protection study Collaborative group 2002), as it not only has a lipid-lowering 
effect, but also an anti-inflammatory effect and the ability to modulate thrombogenesis 
providing plague stabilization (Rice and Lumsden 2006, Hou et al. 2015). However, the 
recent guidelines of the American College of Cardiology/American Heart Association 
(Stone et al. 2014, Robinson and Stone 2015) recommend statin therapy in high-risk CAD 
patients with a greater burden of atherosclerosis and avoiding the treatment in patients with 
lower risk and little atherosclerosis. 
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1.1.3.4  Hypertension and blood pressure 
There is evidence that hypertension is a strong risk factor for all forms of CVD; however, 
the association with PAD is not fully understood (Rahimi et al. 2015). The study by Emdin 
et al. (2015), studying the impact of blood pressure on PAD, showed that systolic pressure 
(SP) is a significant risk factor, as a SP of 20mmHg higher than usual resulted in a 63% 
higher risk of PAD and a 10mmHg higher diastolic blood pressure was associated with a 
35% increase. The severity of the PAD paralleled with the severity of hypertension in the 
Edinburg Artery Study (Fowkes et al. 1992), but a later study concluded that hypertension 
is not significantly associated with the progression of PAD to CLI which puts the impact of 
hypertension into question (Wyss et al. 2015).   
Hypertension and atherosclerosis may be regarded as two effects with one underlying 
cause. Hypertension affects the atherosclerosis by mechanical stress changing the 
endothelial and other cell functions, and atherosclerosis affects hypertension by reduced 
arterial compliance and increased peripheral resistance (Takahashi et al. 1993). A good 
management of hypertension is of great value as the blood pressure potentiates with other 
risk factors, leading to a greater risk of cardiovascular disease events (Mancia et al. 2013). 
 
1.1.3.5 Age 
Age is the most important non-modifiable risk factor, as mentioned earlier both the 
prevalence and incidence of PAD rise sharply with aging (Crigui and Aboyans. 2015). 
Aging also plays an important role in the occurrence of symptoms (Intermittent 
claudication), as the prevalence increases from approximately 3% at the age of 40 years to 
6% at the age of 60 (Norgren et al. 2007). 
 
1.1.3.6 Ethnicity 
After age, the ethnicity is the second most important non-modifiable risk factor. Although 
data on the association of ethnicity with PAD are limited, several recent studies have 
suggested a higher risk among the black population (Guerchet et al. 2012, Zheng et al. 
1997, Criqui et al. 2005, Allison et al. 2006). The higher prevalence of PAD among 
African Americans has been confirmed in the GENOA (Genetic Epidemiology Network of 
Arteriopathy) study—34% for women and 33% for men. The GENOA study also showed 
that the difference in PAD prevalence was associated with different conventional risk 
factors (Kullo et al. 2003). 
 
1.1.3.7  Others 
1.1.3.7.1  Chronic kidney disease 
There is an association between renal insufficiency and PAD, especially in the case of end-
stage renal disease requiring dialysis (O’Hare and Johansen. 2001, Joosten et al.  2014). 
Furthermore, in case of concomitant chronic kidney disease, the poorer outcomes have 
been reported in terms of both leg salvage and mortality (Lacroix et al. 2013).  
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1.1.3.7.2  C-reactive protein (CRP) and fibrinogen 
A recent study showed that the risk of developing PAD is significant and independent, 
with odd ratios of the upper versus lower quartiles of 2.8 for CRP and 2.2 for fibrinogen 
(Ridker et al. 2001).  
 
1.1.3.7.3  Homocystein 
The association of homocystein with PAD has been studied widely, and the findings differ 
dramatically. While a meta-analysis published in 1995 suggested an odds ratio of 6.8 for a 
5micromol/L difference in fasting total homocystein (Boushey et al. 1995), a more recent 
large European case-control study estimated an odds ratio of 1.7 (Graham et al. 1997). The 
suggestion that hyperhomocysteinemia is an independent risk factors has been sustained. 
 
1.1.4 Classification 
Generally, disease progression results in the appearance of symptoms⎯the more severe 
the disease the sicker the patient, leading him/her to seek medical attention. An early onset 
of symptoms results in quicker examination and treatment, which may improve the clinical 
outcome. However, in patients with PAD, the severity of the disease is not parallel to the 
development of symptoms in all cases, as the main factors driving the appearance of 
symptoms are 1) the patient’s activity level and 2) the number of comorbidities, such as 
congestive heart failure, musculoskeletal disease or diabetes, that can prevent the person 
from experiencing warning symptoms (claudication, leg pain) (Norgren et al. 2007). 
 
1.1.4.1 Asymptomatic 
The clinician should suspect PAD in the context of missing or compromised pulses during 
an examination of the lower limb. Lower values of ABI measurements confirm the 
diagnosis—the reduction may vary from mild, i.e. 0.7–0.9, or moderate, 0.5–0.7, to severe, 
<0.5  (Shammas et al. 2007). Therefore, asymptomatic patients with a low ABI may 
develop critical limb ischemia, mainly due to the occurrence of non-healing wounds 
caused by relatively minor trauma (Norgren et al. 2007). This can lead to significant 
functional limitations in daily activities and most severely increase the risk of limb loss.  
 The cumulative incidence of deteriorating from asymptomatic to intermittent claudication 
(IC) over 5 years is 7% (4%–11%) and the cumulative incidence of all-cause mortality and 
CV events over 5 years is 19% (17%–20%) (Sigvant et al. 2016). The effectiveness of 
screening for PAD in asymptomatic and undiagnosed individuals in terms of a reduction in 
all-cause morbidity and mortality has not been determined due to the lack of randomized 
controlled trials (Andras and Ferket 2014). 
 
1.1.4.2 Intermittent claudication 
Claudication is defined as muscle discomfort (pain, cramps, or sense of fatigue) in the 
lower limbs (calf, thigh, or buttocks) related to exertion that relievs by a few minutes of 
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rest (Walker et al. 1990). The symptoms originate from an occlusive lesion that does not 
limit the blood flow at rest but, with exercise, causes a significant decrease in muscle 
perfusion, leading to a mismatch between oxygen supply and the muscle’s metabolic 
demand (Norgren et al. 2007).  
Approximately 10%–35% of patients with PAD will present with classic IC. The 
underlying cause of the arterial occlusion, however, should be confirmed by ABI 
measurement as symptoms with normal values most likely have a different non-vascular 
origin (e.g., nerve root compression, spinal stenosis, arthritis) (Hirsch et al. 2006). The 
cumulative incidence rate of progressing to critical limb ischemia is 46.6 (26.0–67.7), 
corresponding to 21%(12%–29%) over 5 years, and the incidence of all-cause mortality 
and CV events over 5 years is nearly doubled compared to asymptomatic patients (Sigvant 
et al. 2016).  
Today, the therapeutic management consist more of conservative treatment (supervised 
exercise programs, altering modifiable risk factors, antiplatelet therapy) rather than 
invasive interventions (Kobayashi et al. 2015). Regular exercise initiates the growth of 
collateral vessels, and 50% of patients become symptom-free over a 5-year follow-up 
(Dormandy et al. 1999). The amputation rate in claudicants according to the TASC 
document is relatively low, 1%–3% (Norgren et al. 2007), but a more recent review found 
a higher rate of amputations, ranging between 4%–27% (Sigvant et al. 2016).  
 
1.1.4.3  Critical limb ischemia (CLI) 
The problems of CLI are discussed in a separate section; please see section 2.2. 
 
1.1.4.4  Acute limb ischemia (ALI) 
Acute limb ischemia usually presents with a rapid development of rest pain in the limb and 
a loss of pulses. In PAD, the vessel is typically occluded by a thrombus that has formed on 
top of the atherosclerotic lesion. Another cause may be embolization from higher up in the 
vascular tree. Due to minimal or non-existing collaterals, the viability of leg is highly 
threatened and requires emergency treatment (Shammas et al. 2007, Norgren et al. 2007).  
 
1.1.5 Atherosclerotic disease in other vascular territories  
Atherosclerosis causes not only PAD but also CAD and CVD, and they therefore often 
occur together. The PARTNERS study showed that nearly one in three patients with PAD 
suffered from either symptomatic or asymptomatic CAD (Hirsch et al. 2001). The rate of 
co-existing symptomatic CVD seems to be lower compared to CAD, as only roughly 5% 
will have a history of any cerebrovascular event. Despite the low incidence of 
cerebrovascular symptoms, CVD occurs upon ultrasonography in 26%–50% of all 
claudicants (Norgren et al. 2007). There is considerable overlap between the vascular 
territories (Figure 1; Bhatt et al. 2006), which poses particular challenges in terms of 
diagnosis and treatment. 
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Figure 1. The overlap between the vascular territories in patients with multivascular 
disease, calculated from the REACH study (modified from Bhatt et al. 2006). 
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Critical limb ischemia (CLI) 
Critical limb ischemia is the most severe stage of PAD, represented by rest pain in the 
lower extremity or tissue loss with or without gangrene (dry or humid). Its treatment is a 
major burden on health care resources, with poor survival (Barshes et al. 2011). 
 
1.1.6 Definition 
The definition of CLI has evolved over time (Table 1) and still lacks complete consensus. 
The first classification to be introduced, based on clinical symptoms (Fontaine et al. 1954), 
is still in use by some clinicians. A more precise and the latest definition was introduced by 
the Trans-Atlantic Inter-Society Consensus Working Group (TASC) which suggests 
always suspecting CLI in patients who present with foot rest pain lasting more than two 
weeks, or a foot lesion (dry or humid gangrene) (Norgren et al. 2007). Lower values of leg 
perfusion measurements confirm the diagnosis of CLI—these include ankle brachial index, 
toe pressure, ankle pressure, or transcutaneous oxygen perfusion (Table 1).  The lack of 
consensus on the CLI definition may lead to bias when studying the CLI population. 
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Table 1. Evolution of CLI definition 
1954 Fontaine Classification (Fontaine et al.) 
- Stage III: Rest pain caused by arterial insufficiency 
- Stage IV: Ulcer and/or gangrene (dry or humid) caused by arterial 
insufficiency 
1982 International Vascular Symposium Working Party Definition (Bell et al.) 
- Severe rest pain requiring repeated analgesia for at least 4 weeks and ankle 
pressure <40mmHg 
- In the presence of tissue necrosis or digital gangrene, ankle systolic pressure 
(ASP)<50mmHg (diabetics should be defined as a separate group) 
1989 European Consensus Document on Critical Limb Ischemia  
- Severe rest pain requiring analgesia for at least 2 weeks and ASP <50mmHg  
1992 Second European Consensus Document 
- Persistently recurring ischemic rest pain requiring analgesia for at least 2 
weeks or tissue loss (ulceration or gangrene), and ASP <50mmHg and/or toe 
pressure (TP) <30mm 
1997 Rutherford Classification (Rutherford et al.) 
- Grade II, category 4: Ischemic rest pain and resting ASP<40mmHg, flat or 
barely pulsatile ankle/metatarsal pulse volume recording (PVR), or TP< 
30mmHg 
- Grade III, category 5: minor tissue loss and resting ASP<60mmHg, flat or 
barely pulsatile ankle/metatarsal pulse volume recording (PVR), or TP< 40 
mmHg 
- Grade IV, category 6: major tissue loss extending above the metatarsal level, 
functional foot not salvageable, and resting ASP<60mmHg, flat or barely 
pulsatile ankle/metatarsal pulse volume recording (PVR), or TP< 40 mmHg 
2000 Trans-Atlantic Inter-Society Consensus for the Management of Peripheral 
Arterial Disease (TASC Working Group) (Dormandy et al.) 
- Clinical definition: chronic, ischemic rest pain, ulcers or gangrene attributable 
to objectively proven arterial occlusive disease 
- Definition for trials: ASP<50–70mmHg or TP<30–50mmHg or TcPO2 <30–
50mmHg 
2007 Trans-Atlantic Inter-Society Consensus for the Management of Peripheral 
Arterial Disease (TASC II) (Norgren et al.) 
- Chronic ischemic rest pain, and ASP<50mmHg or TP<30mmHg 
- Ulcer or gangrene, and ASP<70mmHg or TP<50mmHg 
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1.1.7 Epidemiology 
Despite the excessive research on CLI, not much is known about the epidemiology. A 
recent meta-analysis estimated a pool prevalence of 800 cases per an adult population of 
100 000 (Biancari et al.  2013). However, the incidence differs within the literature. The 
only prospective population-based study, the Oxford Vascular Study, has estimated an 
incidence of 22/100 000 per year with a sharp increase among the elderly: 67 cases in the 
age group of 65–74 years, 168 cases in the age group of 75–84 years, and 171 cases in the 
age group of ≥85 years (Rothwell et al. 2005). On the other hand, the study by Baser et al. 
(2013), evaluating the US Medicare population aged ≥65 years, reported an incidence of 
200/100 000 per year. A continuing increase in the incidence is expected as the proportion 
of the elderly population is on rise (WHO).  
 
1.1.8 Natural history  
The different approaches to how to treat CLI as well as the varying skills of the clinicians 
in each vascular center makes it very difficult to study the natural history of critical limb 
ischemia objectively (Luther et al. 2000, Bradbury et al. 2002, Paulus et al. 2012). The 
direction of treatment, in terms of revascularization options, has changed dramatically. In 
the late 20th century (1980–1999), only 50% of the patients underwent some form of 
revascularization; approximately 25% received conservative treatment and 25% underwent 
a primary amputation (Dormandy et al. 1999). During the last decade, up to 90% of 
patients with CLI have had an attempt of revascularization, especially in active 
interventional centers (Norgren et al. 2007). A recent retrospective study reviewing 1244 
patients who underwent endovascular treatment reports different one-year overall survival 
and freedom from major amputation rates between patients with rest pain and tissue loss; 
87% and 94% versus 80% and 81%, respectively (Vierthaler et al. 2015). The only 
randomized controlled trial comparing open surgical bypass to endovascular treatment, the 
BASIL (bypass versus angioplasty in severe ischemia of the leg), reported similar overall 
survival and amputation-free survival in both groups at 2 years’ follow-up, but after 2 
years, the clinical outcomes were better in the open surgery group (Bradbury et al. 2010). 
The least biased data on the natural history of the CLI is provided with a group of patients 
that are not suitable for active treatment (endovascular/surgical). Two meta-analyses 
including a total of 13 studies reported similar results: an all-cause mortality rate in one-
year follow up of 22% and a one-year pooled leg salvage rate of 57.4% (Abu Dabrh et al. 
2015, Biancari et al. 2013). Indeed, the mortality and number of major amputations are 
high among patients with untreated CLI, but there is evidence of improvement over time. 
In 1995, Jivegård et al. reported a leg salvage rate of 45% and an amputation-free survival 
rate of 33% over 18 months. One year later, Lepäntalo and Mätzke (1996) studied the 
outcome of 105 patients with 136 critically ischemic legs treated conservatively. At one-
year follow-up, the all-cause mortality was 54% and the amputation rate 46%. 
The exact reason for improvement is unclear, but it is likely related to a prompter diagnosis 
of CLI, improvements in the medical treatment of comorbidities as well as local wound 
care and new therapy techniques (Teraa et al. 2013). 
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1.1.9 Diagnosis  
The diagnosis of critical limb ischemia is based on clinical findings: the patient’s 
anamnesis and physical examination. The majority of the patients do not experience the 
early symptoms—therefore, when examining any patient with leg pain or a foot ulcer, a 
vascular cause should be considered. The foot of a critically ischemic leg is usually pale, 
cold, cyanotic, and without pedal pulses. The tissue loss frequently develops distally to the 
ankle region, and, if not infected, it may form dry gangrene (dry, shrunken and dark 
reddish-black eschar) and become mummified.  The objective investigations of arterial 
flow confirm the CLI diagnosis. The available measurement methods with values 
indicating CLI are listed below: 
1. Ankle pressure (AP): An easy method feasible in primary care centers. Values of < 
50mmHg in chronic ischemic rest pain and <70mmHg in patients with ulcer or 
gangrene indicate CLI.  
 
2. Toe pressure (TP): Measurement performed in vascular laboratories. Values are 
typically <30mmHg in chronic ischemic rest pain and <50mmHg in patients with 
an ulcer, gangrene, or diabetes. 
 
3. Transcutaneous oxygen tension (TcpO2): Measurement performed in vascular 
laboratories. The critical level is <30mmHg. 
 
4. Investigation of microcirculation: These measurements are mainly used as research 
methods. Capillaroscopy (Kluz et al.  2013), indocyanine green angiography 
(Terasaki et al. 2013), laser Doppler fluxometry (Ticcinelli et al. 2014).  
If revascularization is likely to be indicated, the imaging of the lower limb arteries is 
mandatory. The current options are: color-assisted duplex ultrasonography, digital 
subtraction angiography (DSA), computed tomography angiography (CTA), and magnetic 
resonance angiography (MRA). DSA remains the gold standard; however, the drawbacks 
are its invasiveness and high radiation exposure. The evolution of CTA and MRA 
technologies has resulted in high accuracy in the assessment of hemodynamically 
significant stenosis and occlusion, as well as non-invasiveness with lower or no radiation 
exposure (Met et al 2009, Collins et al. 2007).  The low radiation exposure is especially 
important among diabetic patients who are more likely to suffer from chronic kidney 
disease. In case of renal failure or necessity of large volumes of contrast medium for 
complex endovascular procedure, the carbon dioxide angiography is preffered (Cho 2015). 
Therefore, the imaging strategy of DSA as the gold standard is likely to change in the near 
future (Meyersohn et al. 2015). 
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1.1.10 Treatment  
Patients with leg rest pain with or without foot ulcer/gangrene should be evaluated without 
delay. If CLI is suspected the patients should urgently be referred   to a vascular surgical 
unit (Dormandy and Rutherford 2000, Lepäntalo et al. 2000).  
The primary goal of the treatment is to restore the blood flow into the ischemic leg, which 
relieves pain and allows the healing of the ischemic tissue. The importance of restored 
pedal pulsation with foot reperfusion was already emphasized during the last century when 
it was mainly achieved by means of open surgical techniques (Pomposelli et al. 1990, 
Faglia et al.1998).  
Over the last decade, the developments in the endovascular technique have rapidly 
increased the number of these procedures among patients with CLI. This evolution has 
shifted the treatment of CLI towards an “endovascular first” strategy beyond the 
recommendations of TASC II (Table 2), and the number of patients primarily referred for 
open surgical revascularization has decreased significantly (Goodney et al. 2009). This 
shift in the TASC II guidance has not been emphasized enough, and, furthermore, the 
infrapopliteal TASC classification was missing. Therefore, an update of the consensus on 
revascularization strategies for PAD was discussed in a multispecialty panel meeting in 
Örebro, Sweden, in May 2009. The panel also developed a TASC lesion classification for 
infrapopliteal arteries (Jaff et al. 2015). However, consensus regarding the 
revascularization strategy was not achieved, mainly due to lacking definitive high-level 
evidence with an emphasis on clinical and economic effectiveness upon which to base 
treatment decisions (Beard 2008, Schanzer and Conte 2010).  
The choice of treatment method remains highly individual, as it depends on many factors: 
the patient’s current status and comorbidities, the location of the anatomic disease, the 
available technical resources, and the clinician’s experience. 
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Table 2. TASC classification of femoropopliteal lesions and treatment 
recommendations 
 
 
 
1.1.10.1 Infrainguinal bypass surgery (IBS) 
Open surgical bypass has been a standard operation for the vascular surgeon for over 40 
years. A fundamental principle of IBS is to provide unimpeded arterial runoff to the 
selected outflow vessel (Conte 2009). IBS is relevant in cases with extensive superficial 
femoral artery disease, particularly or extensive infrapopliteal lesions (Norgren et al.  
2007).  
There is a significant amount of literature studying the outcome for the great saphenous 
vein conduit with various operative techniques (in situ, transposed, non-reversed, and 
Classification	 Description	of	the	lesion	 Recommended	
treatment	
TASC	A	 -	Single	stenosis	≤	10cm	or	occlusion	≤	5cm	in		length	 Endovascular	
TASC	B	 -	Multiple	lesions	(stenosis/occlusion),	each	≤5cm	
-	Single	stenosis/occlusion	≤15cm	not	involving	the			
		below-knee	arteries	
-	Single	or	multiple	lesions	in	the	absence	of	
		continuous	tibial	vessels	to	improve	inflow	
		for	a		distal	bypass	
-	Heavily	calcified	occlusion	≤	5cm	in	length	
-	Single	popliteal	stenosis	
Endovascular	
TASC	C	 -	Multiple	stenosis	or	occlusion	totaling	>15cm			
		with/without	heavy	calcification	
-	Recurrent	stenosis	or	occlusion	that	needs	
			treatment	after	two	endovascular	interventions	
Open	 surgery	 for	
low-risk	patients	
Endovascular	 for	
high-risk	patients	
TASC	D	 -	Chronic	total	occlusions	of	the	CFA/SFA	
-	Chronic	total	occlusions	of	the	popliteal	artery	
and	proximal	trifurcation	vessel	
Open	surgery	
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reversed), especially in cases of extensive PAD in the infrapopliteal region (Van Damme 
2004, Schanzer et al. 2007, Conte 2009). In the absence of a good-quality saphenous vein, 
another autologous vein (lesser saphenous vein, arm veins) or prosthetic material can be 
used as the conduit (Barshes et al. 2013). The patency of the different vein configurations 
is comparable and the choice primarily depends on anatomic circumstances and the 
surgeon’s preferences (Shah et al. 1995, Schanzer et al. 2007). The prosthetic grafts are 
more dependent on outflow resistance and less tolerant of the low-flow state, which leads 
to poorer patency in long-term follow-up (Johnson and Lee. 2000, Twine and McLain 
2010). Furthermore, an increased risk of wound infection in patients with ischemic tissue 
loss leads surgeons to prefer an autologous vein, as the resistance is better than in 
prosthetic grafts (Bandyk 2008).  
A large randomized trial, Edifoligide for the Prevention of Infrainguinal Vein Graft Failure 
(PREVENT III), reported the primary patency, survival, and limb salvage rates at 1-year 
follow up—61%, 83.8%, and 88.5%, respectively. Peri-procedure mortality occurred in 
2.7%, and surgical wound complications were reported in 4.8% of the patients (Conte et al. 
2006). The only randomized trial comparing bypass surgery to angioplasty in patients with 
severe ischemia, BASIL, reported equal results of amputation-free survival at 6 months. 
However, over a follow-up of 3 to ≥5 years, the surgical group demonstrated a numerical 
trend towards better overall and amputation-free survival (Adam et al. 2005, Bradbury et 
al. 2010).  
Bypass surgery is usually reserved for complex and extensive lesions in patients whose 
health status suggests a >2-year survival (Jaff et al. 2015). Two trials, The Best 
Endovascular versus Best Surgical Therapy in patients with CLI (Menard and Farber 2014) 
and BASIL II, have been launched and will bring answers to the question of whether 
optimal surgery for selected patients with a good-quality saphenous vein is a better choice 
than endovascular therapy. 
 
1.1.10.2 Percutaneous transluminal angioplasty (PTA) 
Endovascular revascularization of a short femoral occlusion was first attempted in 1964 
(Dotter and Judkins); the treatment of infrapopliteal disease has been reported since the 
early 1990s (Iyer et al.). PTA is a mini-invasive procedure, which can be performed under 
local anesthesia. Using the luminal or subintimal technique, the atherosclerotic lesion is 
crossed with a guide wire, and a balloon on catheter, with or without a supporting mesh 
(stent), is passed over into the desired position. Inflating the balloon leads to the dilatation 
of the stenosed or occluded vessel.  
The rapid evolution of technology available for endovascular treatment (sheaths, catheters, 
wires, balloons, stents, drug-device combinations, debulking tools such as cryoplasty or 
excisional atheroctomy) allows technical success even with the most complex of anatomies 
(Laird et al. 2006, DeRubertis et al. 2007, Jaff et al. 2015), which has led to the widespread 
adoption of an endovascular-first approach for CLI patients (Jaff et al.2015). The technical 
success rates differ from study to study, mainly due to the heterogeneous definition of a 
successful procedure (Diehm et al. 2007). A meta-analysis including 30 studies reported a 
pooled estimate of technical success of 89% and a 3-year limb salvage rate of 82.4% 
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(Romiti et al. 2008). The most common procedural complications are bleeding from the 
puncture site followed by a pseudoaneurysm, as well as thrombosis, distal embolization, 
dissections, vessel perforation, renal failure, and cardiac complications; the complication 
rate was reported to be 7%–10% (DeRubertis et al. 2007, Romiti et al. 2008).  
Despite the minimal invasion, the procedure is not without risk, especially in patients with 
co-morbidities—the reported early death rate is 2%–3% (Adam et al. 2005, Haider et al. 
2006, Conrad et al. 2009). Furthermore, there is a high rate of restenosis, 50% at one year 
(Mlekush et al. 2002) and 65% at two years (Haider et al. 2006), resulting in a need for 
repeated interventions, which may be seen as the major limitation of endovascular 
revascularization.  
 
1.1.10.3 Hybrid procedure 
A strategy combining endovascular and open surgical techniques is gaining popularity. In 
many cases, it may offer better inflow, which is managed by endovascular treatment and 
followed by infrainguinal surgical revascularization. The typical case example would be 
combined aortoiliac and infrainguinal disease (Chang et al. 2008, Aho and Venermo 2012). 
 
1.1.10.4 Major amputation 
Major amputation is defined as an amputation above the ankle level, and despite the 
advances and aggressive treatment of CLI, the amputation rates are still high (Abou-
Zamzam et al. 2006).  Primary amputation as an alternative to revascularization is 
indicated in cases where a functional limb can no longer be provided. This applies mainly 
to non-ambulatory elderly patients with flexion contractures, life-threatening infections, 
extensive necrosis that has destroyed the foot, or cases where rest pain cannot be controlled 
(Nehler et al.2003, Norgren et al. 2007).  
A primary amputation is to be considered as the most appropriate treatment for patients 
with severe co-morbidities or very limited chance of successful revascularization due to 
extended PAD (Biancari et al. 2000, Abou-Zamzam et al. 2007). Secondary major 
amputation is performed if vascular reconstruction is no longer possible or if the limb 
continues deteriorate despite the presence of patent reconstruction (Norgren et al. 2007). 
 
1.1.10.5 Pharmacotherapy 
Several pharmacological agents (prostanoids, vasodilators, antiplatelet drugs, 
anticoagulants, and vasoactive drugs) as an alternative to amputation have been tried in 
cases where revascularization is not technically possible (Norgren et al. 2007). Prostanoids 
resulted in an improvement of the clinical picture regarding rest-pain relief, ulcer healing, 
and amputation-free survival (Rufolo et al. 2010), as it protects the endothelium by 
preventing platelets and activating leucocytes. However, the long-term effectiveness and 
safety for the patients is not known; a frequent occurrence of side effects such as facial 
flushing, nausea, vomiting, and diarrhea has been reported (Ruffollo et al. 2010). 
Therefore, prostanoids are rarely used (Norgren et al. 2007).  
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1.1.11 Diabetic foot ulcer (DFU) 
Every year, over a million diabetic patients lose their limb; in other words, an amputation 
is performed every 20 seconds in the world as an outcome of this debilitating disease 
(Boulton et al. 2005). Approximately 80% of diabetes-related lower extremity amputations 
are preceded by a foot ulcer (Hingorani et al. 2016), which develops in 25% of diabetic 
patients during their lifetime (Gregg et al. 2004).  
Risk factors for ulcer development include: neuropathy, severe PAD (CLI), foot deformity, 
limited ankle range of motion, high plantar foot pressures, minor trauma, previous 
ulceration or amputation, and visual impairment (Armstrong et al. 2003, Boulton 2004, 
Morbach et al. 2004, Bowling et al. 2015). Because of the multifactorial process of DFU 
formation, they are usually categorized into three groups: neuropathic, ischemic, and 
neuroischemic (Norgren et al. 2007). An increasing proportion of diabetic patients with an 
ischemic or neuroischemic wound as opposed to neuropathic wounds alone have been 
observed (Morbach et al. 2012, Hingorani et al. 2016). The current estimation shows that 
an ischemic component presents in at least 65% of DFUs (Hinchliffe et al. 2012, 
Armstrong et al. 2013), and the multicenter prospective Europian Study Group on Diabetes 
and the Lower Extremity, EURODILE, observed that the presence of PAD increases the 
annual amputation and mortality rate from 2% to 8% and from 3% to 9%, respectively 
(Prompers et al. 2008).  
Therefore, all patients with diabetes and an ulcer should be referred to vascular centers for 
an evaluation of foot perfusion. A general practitioner can only obtain information on 
pulse pulsation and ABI values, which have been proven unreliable for PAD diagnosis in 
patients with diabetes. The presence of pedal pulses does not conclusively exclude the 
presence of PAD (Rivers et al. 1990, Collins et al. 2006), and ABI may be falsely elevated 
as a result of non-compressible arteries affected by medial calcinosis (Aerden et al. 2011, 
Alvaro-Afonso et al. 2015). A superior reliability has been shown for TP and TcpO2 
measurements (Brownrigg et al. 2016, Hinchliffe et al. 2016, Sonter et al. 2015); the 
effectiveness of one non-invasive bedside investigation, however, proved insufficient for 
the detection of PAD among diabetic patients (Brownrigg et al. 2016, Hinchliffe et al. 
2016). 
Therefore, regardless of the measurements, if there is any doubt concerning the blood 
perfusion, imaging should be performed to evaluate the severity of the atherosclerosis. The 
recent guidelines of the Society for Vascular Surgery in collaboration with the American 
Podiatric Medical Association and the Society for Vascular Medicine (Figure 2) 
recommend a revascularization procedure (endovascular or surgical) in patients with a 
DFU and PAD (Hingorani et al. 2016). The choice of revascularization method is subject 
to the same problems as with non-diabetic CLI patients. The trend towards an 
endovascular first strategy is observed (Faglia et al. 2005), even though clear evidence 
favoring endovascular therapy over open bypass in terms of better clinical outcome is 
lacking (Hinchliffe et al. 2012). More importantly, the presence or absence of infection is 
crucial in the planning of revascularization. An infection increases the likelihood of a non-
healing ulcer three-fold (Prompers et al. 2008), and an aggressive control of the infection 
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with appropriate antibiotics and thorough debridement must therefore be administered 
before or during any type of revascularization (Prompers et al. 2008, Lipsky et al. 2013). 
 
 
 
 
  
Figure 2. Extraction from an algorithm for the prevention and care of a diabetic 
foot. The management of diabetic foot: A clinical practice guideline by the Society 
for Vascular  Surgery in collaboration with American Podiatric Medical 
Association and the Society for Vascular Medicine (modified from Hingorami et 
al. 2016). 
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Pa]ent	develop	ulcer	
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Angiosome theory 
In 1987, Taylor and Palmer introduced the angiosome concept in their anatomical study. 
The angiosome research was conducted due to evolving tissue transfer techniques in 
plastic and reconstructive surgery. The authors’ aim was to investigate the important 
aspects of microvascular anatomy and identify complicated flaps that would not develop 
necrosis due to a lack of arterial supply. 
The investigation was performed on fresh cadavers that showed no obvious evidence of 
PAD. After an injection of the perfusion mixture and careful dissection, a three-
dimensional subtraction picture was taken of the vascular network (Taylor and Palmer 
1987, Inoue and Taylor 1996, Taylor and Pam 1998, Houseman and Taylor 2000). 
 
1.1.12 Definition 
An angiosome is defined as a 3-dimensional unit of each tissue layer between the skin and 
bone supplied and drained by specific vessels (Taylor and Palmer 1987). 
Taylor et al. described in detail the angiosomal distribution of the upper extremity and 
neck (Inoue and Taylor 1996, Houseman and Taylor 2000); the lower extremity was 
mapped from the gluteal area to the ankle region (Taylor and Pam 1998,). Attinger et al. 
(2001, 2006) focused on the distribution in the foot and concluded on the existence of 6 
angiosomes, each supplied by one of the crural arteries and its terminal branches, Figure 3.      
The angiosomal areas and source vessels are described as follows:  
Angiosome 1: Covers the dorsal surface of the foot; the source artery is the arteria 
dorsalis pedis (ADP). 
 Angiosome 2: Covers a small surface of the lateral malleolus; is supplied by the arteria 
peronealis (AP). 
Angiosome 3: Covers the lateroposterior and plantar surface of the heel; the source 
artery is the terminal branch of AP, the calcanear branch.  
 
 Angiosomes 4–6: The main source artery is the arteria tibialis posterior (ATP). As the 
ATP continues distally to the foot, it splits into three main branches supplying three 
separate angiosomes: 4) the mediodorsal and plantar heel via its calcanear branch, 5) 
the medial instep via the medial plantar artery, and 6) the lateral instep and the plantar 
forefoot via the lateral plantar artery. Figure 3A  
Due to multiple arterial variations (Adachi and Hasebe 1928), another distribution of 
angiosomes in the plantar side of foot has been observed (Attinger at al. 2006). The lateral 
plantar artery can be the source for the lateral instep and forefoot, including only the region 
of the fifth toe until the lateral side of the second toe (angiosome 4), which leaves the 
medial plantar artery to be the source of the medial instep and plantar forefoot from the 
hallux to the medial side of second toe (angiosome 3). Figure 3B (Attinger et al. 2006)	
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Some studies even consider the hallux and the medial side of the second toe as a separate 
angiosome—angiosome 7 (Houlind and Christensen 2013). The source artery of the 
hallucal angiosome varies depending on the anatomy. A Japanese study conducted on 100 
cadavers showed that the hallux is supplied either by the ADP (the first dorsal metatarsal 
branch), the lateral plantar artery (the first plantar metatarsal branch) or, secondarily, the 
medial plantar artery (the hallucal branch) (Hamada et al. 1993). Figure 3C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
Figure 3. Angiosomal	distribution (A) and its variations (B, C)  
a, the angiosome of ATA; b, the angiosome of AP including the lateral malleolar angiosome (2); c, 
the angiosome of ATP. 1, dorsal angiosome, source = ADP; 2, lateral malleolar angiosome, source = 
AP; 3, dorsolateral and plantar angiosome, source = calcanear branch of the AP;  4, dorsomedial and 
plantar angiosome, source = calcanear branch of ATP ; 5, medial plantar instep and forefoot 
angiosome, source = medial plantar artery,; 6, lateral plantar foot and forefoot angiosome, 
source = lateral plantar artery and 7, angiosome of the hallux and medial side of the second toe, 
source = dorsal metatarsal artery (78%), plantar metatarsal artery (22%). 
B
)	
A
)	
C
)	
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Several arterial-arterial connections exist between the angiosomes: 1) the so-called “true 
anastomosis”, i.e. arteries with no change in caliber—e.g., the plantar arch connecting to 
the pedal arteries and allowing uninterrupted blood flow to the entire foot despite the 
occlusion of one of the crural arteries (Taylor and Palmer 1987, Attinger et al. 2006, 
Taylor et al. 2013); and 2) the so-called “choke vessels”, i.e. small arteries with a decrease 
in caliber requiring a period of ischemia to open (Aydin and Mavili 2003, Taylor et al. 
2013). However, those connections may be occluded by progressing PAD, especially in 
diabetic patients whose mid- and small-sized arteries occlude due to medial calcinosis. 
Therefore, the tissue of the angiosome with a compromised source artery can suffer from 
severe ischemia. (Clemens and Attinger 2010) 
Most tissue covers two or more angiosomes by receiving arterial blood from another 
angiosomal source artery—e.g., the plantar heel supplied by the calcanear branch of both 
the ATP and AP. Therefore, it is hard to identify an exact junction zone (border) between 
the angiosomes as it usually occurs within the tissue (Taylor and Pam 1998,). 
 
1.1.13 Application in treatment of CLI 
Although the literature states that pulsatile flow to the correct region of the foot is 
necessary to heal ischemic tissue loss (Treiman et al. 2003, Hughes et al. 2004), defining 
such a region for revascularization remains under debate.  
After the introduction of the angiosome concept, the idea of so-called “angiosome-
targeted” revascularization⎯the restoration of blood flow directly to the angiosome 
affected by the ischemic wound—appeared among vascular surgeons (Alexandrescu et al. 
2008, Neville et al. 2009, Iida et al. 2010).  
They hypothesized that direct revascularization may result in a better clinical outcome as 
the perfusion of the ischemic foot, provided by the open line from the abdominal aorta to 
the source artery, should be higher than after indirect revascularization, a procedure on an 
artery that is not related to the affected angiosome.  Direct revascularization according to 
ulcer location has been defined as presented in Table 3.  
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Table 3.  Angiosome-targeted (direct) revascularization based on ulcer location 
according to the angiosome concept (Varela et al. 2010, Söderström et al. 2013, 
Neville et al. 2009, Azuma et al. 2012, Acín et al. 2014, Kret at al. 2014). 
 
 
An exception to obtaining direct revascularization in the case of tissue loss located in the 
forefoot and heel was made due to multiple vascularizations of the angiosomes (Attinger et 
al. 2006, Neville et al. 2009). Allexandrescu et al. (2013) described a different approach of 
angiosome-targeted revascularization for lesions located in the forefoot and heel, 
presenting the ATP as the first choice of arterial reconstruction. 
 The retrospective studies comparing direct versus indirect revascularization in either the 
open surgical group (Neville et al. 2009, Deguchi et al. 2010, Kret et al. 2014), the 
endovascular group (Alexandrescu et al. 2008, Alexandrescu and Hubermont 2011, Iida et 
al. 2010, 2012 and 2014, Södeström et al. 2013, Acin et al. 2014, Jeon et al. 2016, Shiraki 
Ulcer location Direct revascularization Indirect revascularization 
Forefoot 
 (angiosome 1,5,6) ATA/ADP ± ATP/plantar 
arteries AP 
Dorsum of the foot 
 (angiosome 1) ATA/ADP ATP, AP 
Medial instep 
(angiosome 5) ATP with patency of medial 
plantar artery AP, ATA, ADP 
Lateral instep 
(angiosome 6) ATP with patency of lateral 
plantar artery AP, ATA, ADP 
Heel 
(angiosome 3,4) ATP/AP ATA, ADP 
Lateral malleolus 
(angiosome 2) AP ATA, ADP, ATP 
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et al. 2015), or both groups supported the superiority of angiosome-oriented 
revascularization (Kabra et al.2013, Lejay et al. 2014). The two recent meta-analyses, 
including a total of 15 retrospective studies, also reported that wound healing and limb 
salvage is better in favor of direct revascularization, especially in patients with diabetes 
(Biancari and Juvonen. 2014, Bosanquet et al. 2015).  
Despite the promising results, the importance of the concept has been contradicted. For 
example, in revascularization by surgical bypass, Varela et al. (2010) and Rashid et al. 
(2013) suggested that the wound healing more likely depends on the quality of pedal arch 
rather than the angiosome-targeted approach. One of the main flaws of the angiosome 
concept is the unclear definition of direct revascularization in cases where the wound 
spreads over several angiosomes, which is the case in most of the diabetic patients (Aerden 
et al. 2014). Only Iida et al. (2012, 2013 and 2014) mention this problematic issue in their 
studies, without a consensus, however. In their study from 2012, direct revascularization is 
explained as a procedure on all source arteries of the angiosomes involved in the lesion, 
yet in the studies published in 2013 and 2014, it is defined as revascularization of the 
angiosome with the largest surface involved in the wound.  
Furthermore, a randomized trial that would compare direct versus indirect 
revascularization and take collateral vascularization into account is lacking. The likelihood 
that such a trial would be forthcoming is minimal due to the complexity of randomizing 
patients based on concurrent angiography and the need to provide the safest form of 
revascularization. Therefore, it has been suggested that before a widespread adoption of 
angiosome-guided revascularization as a novel technique in vascular reconstruction, more 
clinical evidence in the form of well-structured, prospective studies must become available 
(Sumpio et al. 2013). 
 
1.1.14 Wound healing  
The available evidence favors angiosome-oriented revascularization in terms of better 
wound healing rates. In the initial series including 52 distal bypasses, the ulcer failed to 
heal in 9% of the cases in the direct group versus 38% in the indirect group (Attinger et al. 
2006). A larger series of 539 consecutive CLI patients with Rutherford 5–6 ischemia and 
isolated below-knee arterial lesions who had neither diabetes mellitus or an infected 
wound, Iida et al. (2014) observed a higher complete wound healing rate at 1 year in the 
direct group as adjusted for propensity score, 75% vs. 64%, in the indirect group. The other 
two studies reporting data from a propensity-score-matched analysis showed a trend 
towards a better wound healing rate after direct revascularization (HR 0.72, 95% CI 0.50–
1.04, I2 29%) (Azuma et al. 2012, Södeström et al. 2013).  
Among diabetic patients, Alexandrescu et al. (2008) were the first to report the benefit of 
the angiosome concept analyzing 98 diabetic patients with CLI and a foot ulcer (Wagner 
grade 1–4). The study reported complete wound healing in 79% of the treated limbs. The 
propensity score analysis in a study by Södeström et al. (2013) adjusted for diabetes, age, 
sex, CAD, gangrene, and estimated glomerular filtration rate <30mL/min/1.73m2 or 
dialysis, showed a significantly better wound healing rate in the direct group (HR 1.97; 
95% CI 1.34–2.90; p<0.001). In a multicenter retrospective study from Japan, the median 
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wound healing time among diabetic patients with an isolated infrapopliteal arterial lesion 
was 146 days, and indirect revascularization was one of the independent predictors of 
delayed wound healing (Shiraki et al. 2015). 
The meta-analysis by Biancari and Juvonen  (2014) reported that the risk of an unhealed 
wound was significantly lower after direct revascularization (HR 0.64, 95% CI 0.52–0.8, I2 
0%, four studies included) compared to indirect revascularization. Data regarding wound 
healing in the meta-analysis by Bosanquet et al. (2014) included 11 papers and showed a 
significantly improved wound healing rate after direct revascularization, with an odds ratio 
of 0.40 (95% CI 0.29–0.54, p <.00001), in both the bypass and the endovascular group. 
 
1.1.15 Limb salvage 
In the field of vascular surgery, leg salvage means the preservation of a functional foot 
without the need for a leg prosthesis (Tefera et al. 2005). A clear benefit of direct 
revascularization is not as evident in regard to this matter as in wound healing rates. 
 Limb salvage rates are reported in 15 papers including 1,775 limbs (Acin et al. 2014, 
Alexandrescu et al. 2008, Azuma et al. 2012, Fossacea et al. 2013, Iida et al. 2012, Kabra 
et al. 2013, Kret et al. 2014, Lejay et al. 2013, Neville et al. 2009, Osawa et al. 2013, 
Oshima et al. 2012, Rashid et al. 2013, Södeström et al. 2013, Soon et al. 2012, Varela et 
al. 2010 ).The heterogeneity among these studies is high (I2=73%), and the meta-analysis 
showed improved leg salvage rates in the direct group (OR 0.77, 95% CI 0.13–0.45) 
(Bosanquet et al. 2014). 
An analysis of 6 studies (Varela et al. 2010, Blanes et al. 2011, Alexandrescu et al. 2011, 
Iida et al. 2012, Lejay et al. 2013 and Kabra et al. 2013) resulted in pooled leg salvage 
rates at of 86.2% in the direct group vs. 77.8% in the indirect group 1 year, and 84.9% vs. 
70.1%, respectively, at 2 years (Biancari and Juvonen 2014). The benefit of angiosome-
guided revascularization in terms of leg salvage was confirmed among diabetic patients 
(HR 0.48, 95% CI 0.31–0.75, I2 0%, three studies included) (Biancari and Juvonen 2014). 
 
1.1.16 Amputation-free survival (AFS) 
Amputation-free survival defined as the avoidance of major amputation is reported in only 
3 studies (Iida et al. 2012 and 2014, Söderström et al. 2013). The study by Iida et al. (2014) 
reports no significant difference between direct and indirect revascularization, 60% vs. 
57% at 24 months, respectively. AFS at 1 year in patients with diabetes whose wound 
healed was 41% in the direct group compared to 26% in indirect group. However, the 
overall AFS at 1 year showed no difference between the groups, 65% for direct vs. 61% 
for indirect (Söderström et al. 2013). The meta-analysis reported only a trend towards 
better results in favor of angiosome-oriented revascularization (HR 0.81, 95% CI: 0.61–
1.06, I2 25%) (Biancari and Juvonen 2014). 
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AIMS OF THE PRESENT STUDY 
 
The main purpose of this study was to analyze the use of the angiosome concept in the 
treatment of patients with CLI and tissue loss (Rutherford 5–6). (Figure 4) 
 
The specific aims were to: 
 
1. Evaluate of the feasibility of angiosome-guided endovascular revascularization 
and asses the topography of the ischemic tissue loss in relation to the angiosome 
concept. (I)  
 
2. Compare and investigate the factors influencing the complete healing time of 
ischemic tissue lesions, including the healing of the incisional wounds, according 
to the angiosome concept (II, III). 
 
3. Compare the clinical outcome of angiosome-guided bypass surgery and 
endovascular therapy of the infrapopliteal arteries as a first-line revascularization 
strategy in patients with CLI and tissue loss (II), and in diabetic patients with CLI 
and tissue loss (III).   
 
 
4. Evaluate which of the two existing angiosome-targeted definitions is more usable 
in clinical practice (IV). 
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Study IV 
Patients treated between 2010-2013 
N=658 
DR performed? 
YES NO 
Definition A Definition B 
Wound healing? Leg 
salvage? 
Study III 
Diabetic patients treated  
between 2008-2013 
N=545 
DR performed? 
YES NO 
Bypass PTA 
Study II 
Patients treated  
between 2010-2013 
N=744 
Wound healing? Leg 
salvage? 
Study I 
Patients treated in 2012  
N=160 
Number of vessels Possible to 
 revasculirize?  
N=1 N=2 N=3 
DR performed? 
YES NO Reason? 
Patients with CLI and tissue loss that were treated by infrapopliteal revascularization between 2008-2013 
N=1306 
Figure 4. Flowchart showing the design of each study 
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PATIENTS AND METHODS 
 
The Institutional Review Board of Helsinki University Hospital (HUH) approved all of the 
studies. From hospital records, we retrospectively gathered 1306 patients with CLI and 
tissue loss who underwent infrapopliteal revascularization at our clinic between January 
2008 and December 2013. Our prospective HusVasc registry provided the following 
information: indication for revascularization, specific revascularization details, type of 
local surgery, and patient demographics (Table 4).  The comorbid diseases were verified 
as follows: 
CAD-documented coronary artery disease, previous coronary bypass surgery, history 
of myocardial infarction, angina pectoris or ischemic changes on ECG, 
CVD- history of stroke or transient ischemic attack, 
Pulmonary disease- chronic obstructive pulmonary disease or astma, 
Diabetes mellitus- hyperglycemia requiring diet or medication, 
Hypertension- medication for hypertension or blood pressure repetadly > 
160/90mmHg, 
Dyslipideamia- medication for hyperlipidemia or fS-cholesterol > 5mmol/L or S-
LDLcholesterol > 3mmol/L, 
Hearth failure-documented heart failure, 
Smoking- current smoking. 
HusVasc registry data were manually crosschecked with the patient records, and missing 
data was retrieved, such as wound healing time and amputation status.  Statistics Finland 
provided the data on the patients’ deaths. 
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Table 4. Number of patients included in each study and their demographics  
 
 
 
 
 
Variable Study I      
(%) 
Study II     
(%) 
Study III 
(%) 
Study IV 
(%) 
Number of included patients 160 744 545 658 
Age: median 
(range) 
76 
(42–93) 
74 
(39–102) 
73 
(39–94) 
74 
(39–102) 
Female 60 (37.59) 274 (36.8) 170 (31) 246 (37.3) 
Smoking 20 (12.5) 108 (14.5) 69 (12.7) 96 (14.6) 
Pulmonary disease 20 (12.5) 83 (11.2) 49 (9.9) 77 (11.7) 
Atrial fibrillation 59 (36.9) 216 (29.0) 136 (25) 202 (30.7) 
Hypertension 98 (61.3) 468 (62.9) 516 (94.7) 417 (63.4) 
Dyslipidemia 88 (55.0) 191 (25.7) 148 (27.2) 166 (25.2) 
Diabetes mellitus 107 (66.9) 461 (62.0) 545 (100.0) 412 (62.6) 
Coronary artery disease 63 (39.4) 270 (36.3) 224 (41.1) 242 (36.8) 
Hearth failure 24 (15.0) 91 (12.2) 62 (11.4) 85 (12.9) 
CRP: median 
(range) 
51 
(3–263) 
52 
(3–315) 
48 
(2–315) 
52 
(3–315) 
Cerebrovascular disease 28 (17.5) 104 (14.0) 74 (13.6) 94 (14.3) 
Estimated glomerular 
filtration rate: median 
(range) 
50 
(7-<60) 
39 
(4-<60) 
43 
(4-<60) 
39 
(4-<60) 
Haemodialysis 14 (8.8) 44 (5.9) 41 (7.5) 42 (6.4) 
Kidney transplantation 7 (4.4) 15 (2.0) 15 (2.8) 12 (1.8) 
Type of revascularization     
Endovascular 
revascularization 
162 (100) 503 (67.3) 316 (58) 445 (67.6) 
Surgical revascularization - 241 (32.7) 229 (42.0) 213 (32.4) 
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Wound location  
The location and severity of the tissue loss was obtained by reviewing our clinical notes. 
Photographs were taken in one in eight cases. We adopted the general scheme of 
angiosomal distribution to evaluate the number of affected angiosomes (Figure 5). 
 
 
 
 
 
 
Figure 5. General scheme of angiosomal distribution (Attinger et al. 2006, Alexandrescu 
et al. 2012, Iida et al. 2010, Varela et al. 2010, Sumpio et al. 2013, Söderström et al. 2013)  
a, angiosome of ATA; b, angiosome of AP; and c, angiosome of ATP. 1, Dorsal angiosome; 2, 
angiosome of lateral malleolus; 3, dorsolateral and plantar angiosome; 4, dorsomedial and 
plantar angisome; 5, medial plantar instep and forefoot angiosome; 6, lateral plantar foot and 
forefoot angiosome  
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Run-off arteries 
We retrospectively reviewed the preoperative angiograms (studies I–IV); the status of leg 
and foot arteries was quantified according to the Society for Vascular Surgery 
(SVS)/International Society for Cardiovascular Surgery (ISCVS) scoring system of 
angiographic appearance as follows: 0, normal or minimal evidence of disease; 1, 20%–
49% stenosis; 2, 50%–99% stenosis; 2.5, occluded less than halfway; 3, occluded through 
most of the length. The infrapopliteal arteries that scored SVS/ISCVS 2, 2.5, and 3 with 
patent outflow were considered candidates for endovascular treatment (studies I–IV).  
After analyzing the number of arteries feasible for endovascular treatment, we divided the 
patients into 3 groups: group 1 (G1) representing patients with only one crural artery 
suitable for revascularization, group 2 (G2) containing patients with two crural arteries 
fulfilling the conditions for angioplasty, and group 3 (G3) containing patients with all three 
crural arteries as an option for revascularization (Study I). 
In cases of patients who underwent surgical bypass and whose angiograms were missing, 
the outflow arteries and leg status were evaluated based on the preoperative MRA (study 
II–IV). 
 
 
Angiosome-targeted revascularization 
We defined direct revascularization as a procedure on the artery supplying the angiosome 
affected by an ischemic lesion. For the lesions located in the forefoot or heel, 
revascularization of any of the affected angiosomes was accepted into the direct group 
(definition A). In cases of a foot ulcer spreading over several angiosomes and not located 
in the forefoot or heel, direct revascularization was defined as a procedure on the artery 
supplying the largest surface of the angiosome involved in the lesion. If the patient 
suffered from multiple foot ulcers located in separate angiosomes, all affected angiosomes 
had to be revascularized in order to count as direct revascularization (studies I–IV).   
In the last study (study IV), we compared the conventional definition of direct 
revascularization to a different one presented in the literature (definition B), targeting 
only the posterior tibial artery/plantar arteries for a lesion located in the forefoot or heel 
(Alexandrescu 2013). 
In order to evaluate whether direct revascularization was achieved, all postoperative 
angiograms were restrospectively reviewed and manually crosschecked with the HusVasc 
register (I–IV). 
Wound care 
The wound care protocol depended on the characteristics of each lesion: surgical 
debridement of necrotic tissue, revision of infected ulcers, and skin graft application in 
cases of impossible primary or secondary closure. Patients with infected wounds received 
adequate antimicrobial therapy (II–IV). 
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Follow-up 
After the revascularization, patients remained under routine surveillance at the outpatient 
clinic. A vascular nurse carried out duplex ultrasound examinations of the revascularized 
artery and followed the foot status; a vascular surgeon was consulted if necessary (e.g. 
signs of re-stenosis, non-hwaling or worsening of the wound) After PTA, the visits were 
scheduled at 1, 3, and 6 months, and in the case of a bypass graft at 1, 3, 6, and 12 months. 
If the wound remained open at the last routine duplex surveillance, the patient continued to 
visit to the outpatient clinic until the wound was fully healed. The follow-up ended if the 
patient underwent a new infrainguinal bypass due to a failure of the primary intervention 
(endovascular or surgical), a major amputation due to a non-healing foot ulcer, or if the 
patient died (II–IV). 
 
Outcome measures 
We evaluated 1) how often an ischemic lesion is located in one angiosome and 2) the 
reasons for not achieving direct revascularization in cases where the angiosomal artery 
was suitable for endovascular therapy (study I). We compared the outcomes of direct and 
indirect surgical versus endovascular revascularization (studies II–III), and direct versus 
indirect revascularization using the two definitions (study IV). The primary outcome 
measures were wound healing and leg salvage (II–IV). 
 
 
Statistical analysis 
For statistical analysis, we used SPSS v. 22.0 statistical software (II–IV) and MS Excel 
2003 (study I). Continuous variables were reported as mean and standard deviation, and 
nominal variables as absolute number and percentage. Pearson’s Chi-square test, Fisher’s 
exact test and the Mann-Whitney U test were used for univariate analysis. Long-term 
outcome was assessed by Kaplan-Meier’s method with the log-rank test and the Cox 
proportional hazards method (II–IV). 
Differences between study groups were adjusted by estimating a propensity score. The 
propensity score was calculated by means of non-parsimonious logistic regression. (IV)  
Hosmer-Lemeshow’s test was used to assess the regression model fit. The calculated 
propensity score was employed for one-to-one matching as well as to adjust for other 
variables in estimating their impact on the postoperative outcome. One-to-one propensity 
score matching between study groups was performed according to a caliper width equal to 
0.2 times the standard deviation of the calculated propensity score’s logit. Outcome in the 
propensity-matched pairs was evaluated by Kaplan-Meier’s methods as well as the Cox 
regression method. P<0.050 was considered statistically significant (II). 
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RESULTS 
The feasibility of the angiosome concept (I) 
A total of 161 legs (160 patients) undergoing primary infrapopliteal angioplasty in 2012 
were included. The wound(s) interfered with more than one angiosome in 75.8% of the 
cases. (Figure 6)  
 
 
  
 
 
 
 
 
 
Figure 6. The number of affected angiosomes in 161 legs 
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1	angiosome	
2	angiosomes	
3	angiosomes	
4	angiosomes	
5	angiosomes	
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Of all the affected extremities, 33% had only one crural artery suitable for 
revascularization (G1); the remaining 2 arteries were either without any sign of disease 
(n = 17) or occluded (n = 36) with no patent outflow (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The number of arteries suitable for revascularization 
33%	
55%	
12%	
1	crural	artery	(G1);	n=53	
2	crural	arteries	(G2);	n=88	
3	crural	arteries	(G3);	n=20	
	
	
44	
Out of the overall 161 extremities, direct flow was achieved in 98 (60.9%) legs and 
indirect flow via non-targeted revascularization in 63 (39.1%) legs. Direct 
revascularization was possible in 129 (80.1%) legs and performed in 98 (75.9%) cases. 
The reasons behind the 31 cases where direct PTA was possible but not performed were as 
follows: (1) it was attempted without success (n = 9) and another vessel was then 
revascularized; (2) the occlusion was long (n = 14), resulting in revascularization of 
another vessel; and (3) unknown reason (n = 8). Table 5. 
	
	
	
	
	
	
Number of arteries 
suitable for PTA 
DR possible 
(%) 
DR  
achieved 
(%) 
DR not achieved 
 
Failed 
(%) 
Long 
occlusion (%) 
Unknown 
(%) 
1 33 (62.3) 26 (78.8) 2 (6.1) 3 (9.1) 2 (6.1) 
2 76 (86.4) 57 (75.0) 6 (7.9) 8 (10.5) 5 (6.6) 
3 20 (100.0) 15 (75.0) 1 (5.0) 3 (15.0) 1 (5.0) 
Total 129 (80.1) 98 (75.9) 9 (7.0) 14 (10.9) 8 (6.2) 
Table 5. Feasibility and success rate of direct revascularization (DR) in relation to 
the number of crural arteries suitable for PTA. 
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Interestingly, a higher chance that the angiosomal artery will be a candidate for 
revascularization was observed with wound(s) spreading over 2 or 3 angiosomes (Table 
6). 
 
 
Table 6. Feasibility and success rate of direct revascularization (DR) in relation to the 
number of affected angiosomes. 
 
 
Number of affected 
angiosomes 
DR possible 
(%) 
DR achieved 
(%) 
DR not achieved 
 
Failed 
(%) 
Long 
occlusion (%) 
Unknown 
(%) 
1 27 (69.2) 22 (81.5) 2 (7.4) 2 (7.4) 1 (4.2) 
2 65 (86.7) 47 (72.3) 6 (9.2) 7 (10.7) 5 (7.7) 
3 35 (83.3) 29 (82.9) - 5 (11.9) 1 (2.4) 
4 1 (25.0) 0 (0.0) 1 (100.0) - - 
5 1 (100.0) 0 (0.0) - 1 (100.0) - 
Total 129 (80.1) 98 (75.9) 9 (7.0) 15 (10.9) 7(6.2) 
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The importance of the angiosome concept—bypass surgery vs. PTA (II) 
The comparison of direct and indirect revascularization between the revascularization 
methods comprises 744 consecutive patients; 503 underwent PTA and 241 surgical bypass 
between January 2010 and June 2013. Out of all cases, direct revascularization was 
achieved in 55%. 
 
1.1.17 Wound healing 
The Cox proportional hazards analysis revealed that direct revascularization (p=0.036, HR 
1.294, 95%CI 1.017–1.647), bypass surgery (p<0.0001, HR 1.791, 95%CI 1.412–2.272), 
C-reactive protein ≤ 10 mg/dL (p=0.005, HR 1.416, 95%CI 1.110–1.806), and fewer 
affected angiosomes (p=0.024, HR 0.854, 95%CI 0.744–0.979) improved the healing 
potential. When adjusted for the number of affected angiosomes and C-reactive protein ≤ 
10 mg/dL, direct bypass was associated with a significantly higher rate of wound healing 
than indirect angioplasty (p<0.001, HR 2.265, 95%CI 1.605–3.196). Interestingly, indirect 
bypass also achieved better wound healing rates than PTA independently of the 
angiosome-oriented strategy (p=0.001, HR 1.890, 95%CI 1.292–2.766) (Figure 8) 
 
 
Figure 8. Adjusted Cox proportional hazards estimates of wound healing according 
to treatment method and angiosome-targeted revascularization (p<0.0001). 
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1.1.18 Leg salvage 
Direct revascularization was associated with a trend towards improved leg salvage 
(p=0.065, Table 7). The Cox proportional hazards analysis demonstrated that an increasing 
number of affected angiosomes (p<0.0001, HR 1.439, 95%CI 1.206–1.717), atrial 
fibrillation (p=0.028, HR 1.499, 95%CI 1.046–2.149), C-reactive protein > 10 mg/dL 
(p=0.002, HR 1.952, 95%CI 1.271–2.997), CKD class 5 (p=0.002, HR 2.285, 95%CI 
1.354–3.856), and indirect revascularization (p=0.014, HR 1.531, 95%CI 1.088–2.154) 
were independent predictors of major amputation.  
 
 
1.1.19 Propensity score 
A total of 252 pairs were included in the analysis. Direct revascularization was associated 
with significantly better leg salvage and a trend towards improved wound healing (Table 
7).  
When adjusted for propensity score and treatment method (bypass surgery vs. angioplasty), 
direct revascularization was associated with a significantly higher wound healing rate 
(p=0.046, HR 1.295, 95%CI 1.005–1.668). Direct revascularization yielded a significantly 
lower risk of major amputation (p=0.010, HR 0.637, 95%CI 0.452–0.897) and better 
amputation-free survival (p=0.037, HR 0.788, 95%CI 0.630–0.986) in the propensity-
score-adjusted analysis (Figure 9). 
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Figure 9. Propensity-score-adjusted hazard of major amputation according to 
angiosome-targeted and non-targeted revascularization (p=0.010, HR 0.637, 95%CI 
0.452–0.897). 
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Table 7. One-year follow-up outcome of patients who underwent direct or indirect 
infrainguinal revascularization for critical limb ischemia. Data are reported for the 
overall population and propensity-score-matched pairs. 
 
Outcome	end	point	
Overall	series	 Propensity-matched	pairs	
Indirect	
336	pts	
Direct	
408	pts	
p-
value	
Indirect	
252	pts	
Direct	
252	pts	
p-
value	
Wound	healing	 69.2%	 72.1%	 0.071	 67.3%	 71.6%	 0.058	
Survival		 77.1%	 78.5%	 0.364	 77.0%	 76.0%	 0.741	
Leg	salvage	 77.5%	 82.7%	 0.065	 74.7%	 84.1%	 0.019	
Amputation-free	survival	 62.2%	 66.5%	 0.064	 59.9%	 65.3%	 0.154	
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Role of the angiosome concept in diabetic patients—bypass vs. PTA (III)  
The cohort consists of 545 patients, 316 of whom underwent PTA and 229 surgical bypass 
between January 2008 and December 2013. The overall success rate of direct 
revascularization was 59.4%. 
 
1.1.20 Wound healing 
The overall wound healing rate at one-year follow-up was 60.3%. The highest rate was 
achieved after direct bypass (77%) and the worst after indirect PTA (52%). The Cox 
proportional hazards analysis showed that number of affected angiosomes<3 (HR 1.37, 
95%CI 1.01–1.84) and Type of the procedure were independently associated with wound 
healing, and the poorest wound healing was seen after indirect PTA (p=0.001; Figure 10). 
 
Figure 10. Kaplan-Mayer estimates for wound healing in diabetic patients who 
underwent infrapopliteal revascularization 
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1.1.21 Leg salvage 
The overall amputation rate at one year was 25.1%. Cox proportional hazards analysis 
indicated that haemodialysis compared to patients with no haemodialysis (HR 2.55, 95%CI 
1.49-4.38), C-reactive protein≥10 mg/dL (HR 2.05, 95%CI 1.45–2.90), atrial fibrillation 
(HR 1.54, 95% CI 1.05-2.26) and number of affected angiosomes>3 (HR 1.75, 95%CI 
1.24-2.46) were significantly associated with poor leg salvage. The indirect PTA predicted 
poorest leg survival (Figure 11). 
 
 
Figure 11. Kaplan-Mayer estimates for leg salvage in patients who underwent 
infrapopliteal revascularization, (p=0.041). 
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The outcome difference of the two angiosome-targeted definitions (IV) 
This retrospective study included 658 consecutive patients who underwent either PTA or 
surgical bypass of the infrapopliteal arteries between January 2010 and July 2013. When 
applying definition A—targeting any involved angiosome in the wound that is located in 
the forefoot or the heel—367 (55.8%) cases fulfilled the criteria for direct 
revascularization. Applying definition B—targeting only ATP as the source of the forefoot 
and heel angiosomes—the number of cases with direct revascularization decreased 
significantly, n=198 (30.1%, p<0.05). 
Unadjusted actuarial analysis showed that, irrespective of the definition (A or B), direct 
revascularization yielded better wound healing and leg salvage rates when compared to 
indirect revascularization. A propensity-score-adjusted analysis showed that, when 
definition A was adopted, direct revascularization was associated with significantly better 
wound healing and leg salvage rates, whereas when definition B was applied, direct 
revascularization was associated only with significantly better wound healing (Table 8).  
The prognostic ability of definition A was confirmed in a Cox proportional hazards 
analysis as adjusted for diabetes, estimated glomerular filtration rate, C-reactive protein, 
revascularization method, the number of affected angiosomes, and the presence of an intact 
pedal arch (Table 8). When both direct revascularization definitions were included in the 
latter regression model, only definition A was associated with better wound healing 
(p=0.040, HR 1.286, 95%CI 1.012–1.635) and a lower risk of major amputation (p=0.038, 
HR 0.698, 95%CI 0.497–0.980).  
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Table 8. The outcome of patients who underwent direct infpopliteal revascularization 
according to the two different definitions. Data are reported for the adjusted 
propensity-score-matched pairs and Cox proportional hazard  
	
Definition		A	
	
Definition		B	
Outcome	end-
points	
p-value	 HR	(95%CI)	 p-value	 HR	(95%CI)	
Wound	healing	
	 	 	 	 	
Propensity	score	 0.044	 1.291	(1.007–1.656)	 0.029	
1.321	(1.029–
1.695)	
Cox	proportional	
hazard	 0.037	 1.294	(1.016–1.648)	 0.060	
1.267	(0.990–
1.621)	
Major	
amputation	 	 	 	 	 	
Propensity	score	 0.047	 0.706	(0.501–0.996)	 0.096	
0.697	(0.456–
1.066)	
Cox	proportional	
hazard	 0.044	 0.703	(0.847–0.990)	 0.045	
0.652	(0.429–
0.990)	
Mortality	
	 	 	 	 	
Propensity	score	 0.938	 0.990	(0.761–1.286)	 0.087	
0.764	(0.561–
1.040)	
Cox	proportional	
hazard	 0.356	 0.886	(0.685–1.146)	 0.043	
0.733	(0.543–
0.991)	
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DISCUSSION 
 
 
Critical limb ischemia significantly affects the quality of life and mortality, and the number 
of patients suffering from end-stage PAD is raising due to the aging of the population and 
the increasing incidence of DM (WHO, Armstrong et al. 2014). Therefore, the need to treat 
CLI due to leg rest pain or a foot ulcer has become more frequent over the last decade. 
Advancing endovascular technologies opened the possibility for a less-invasive treatment 
of extensive lesions, even in infrapopliteal segments. Historically, achieving one open line 
to the foot was considered satisfactory, but studies showed that the random reconstruction 
of a single infrapopliteal artery yields a poor clinical outcome as it resulted in refractory 
ulcers with a relatively high amputation rate of 10%–18% (Khan et al. 2009, Blevins  and 
Schneider 2010). 
The angiosome concept, originally implemented in plastic surgery, brought anatomical 
insight into the clinical strategy of CLI treatment. Focusing on revascularizing the feeding 
artery of the ischemic angiosome led to the hypothesis of improved wound healing and leg 
salvage rates. Neville et al. (2009) observed 48 patients with non-healing ulcers and found 
that applying the angiosome concept resulted in better outcomes. After this finding, 
extensive research has been carried out on angiosome-targeted revascularization. A meta-
analysis of 15 recent studies showed that the main benefits of direct revascularization 
prevail in improved wound healing rates; the effect of direct revascularization in terms of 
better leg salvage rates, however, was lost in certain sensitivity analyses (Bosanquet et al. 
2014). 
One of the main criticisms of the angiosome concept remains the nonexistence of 
randomized trials and the inconsistent methodologies of the papers that are all 
retrospective—non-standardized decision-making concerning direct revascularization may 
result in the selection of different vessels, constituting a serious source of bias (McCallum 
and Lane 2014, Bosanquet et al. 2014). While direct revascularization is achieved in 
approximately 60% of the patients in open surgery groups (Azuma et al. 2012, Rashid et 
al. 2013, Lejay et al. 2014, Kret et al. 2014), the range of technical success in endovascular 
groups differs dramatically. A study by Södeström et al. (2013) that investigated diabetic 
patients with a foot ulcer reports a technical success rate of 48%, while Alexandrescu et al. 
(2008) achieved direct revascularization in 82% of diabetics. The significant difference in 
technical success rates between the studies can be explained by the diversity of skills 
between individual vascular centers as well as different angiosome-targeted approaches. 
The mean success rate of achieved direct revascularization among EVT is roughly 62% 
(Fosacecca et al. 2013, Acin et al. 2014, Alexandrescu et al. 2008 and 2011, Oshima et al. 
2013, Iida 2013 and 2014, Söderström et al. 2013, Shiraki et al. 2015, Zheng et al. 2016).  
We investigated the feasibility of angiosome-targeted revascularization in patients that 
were selected for primary endovascular therapy, and our results showed that one in three 
patients had only one crural artery suitable for the EVT. In about one third of the cases 
where the source artery was suitable for EVT, the approach was attempted without success 
and an easier artery then selected; in roughly half of the cases, it was not even attempted 
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because of a long lesion. Furthermore, in only 24% of the patients, the wound was isolated 
to a single angiosome. In the literature, the definition of direct revascularization for 
wounds spreading over several angiosomes is scarce and inconsistent. Iida et al. (2013, 
2014) targeted the largest surface affected; due to the dual blood supply of the heel and 
digits, however, it is difficult to correctly define the direct revascularization of these 
regions. Two different approaches of direct revascularization for wounds spreading over 
the forefoot and heel are available, as mentioned in methodology. We compared the 
definitions in our last study, and, although both were associated with better wound healing, 
targeting only the posterior tibial artery did not predict leg salvage when the risk factors 
were adjusted with propensity score analysis. Furthermore, it was less successful clinically, 
as the technical success rate of achieved direct flow was 30%, due to the fact that the 
clinician was limited to only one crural artery as an option for direct revascularization. 
Based on our findings described above, it seems that, with a treatment policy of 
“endovascular first,” we have to accept a certain number of indirect revascularizations, 
instead of treating suitable cases with targeted bypass which yielded the best clinical 
outcomes in our second and third study. Additionally, we found that indirect EVT yields 
the poorest leg salvage and was, together with wound infection, an independent predictor 
of major amputation, while an angiosome-targeted strategy in surgical bypass seems to be 
of less value. 
In 1999, Berceli et al. studied 400 patients who underwent dorsal pedal bypass and 
reported similar wound healing rates for heel and forefoot ulcers (Berceli et al. 1999). This 
contradicts the angiosome-targeted hypothesis, but can be explained by the importance of 
the collaterals between each angiosome. Attinger et al. (2006) stated that the angiosome of 
the heel is unique by its dual supply that has arterial-arterial connections with the ADP. 
Therefore, the wound healing can be similar as the angiosome of the heel receives 
retrograde blood flow via this true anastomosis. Varela et al. (2010) addressed the 
overlooked importance of collaterals and reported that revascularization through collateral 
vessels yielded similar results as direct revascularization: the respective wound healing 
rates at 12 months were 92% vs. 85%, and the respective leg salvage rates at 24 months, 
93% vs. 88%. Also, Rashid et al. (2013) reported the superiority of the quality of the pedal 
arch when compared to the angiosome-targeted strategy in bypass surgery. However, in the 
case of absent collaterals, direct revascularization seems to be the best option, as also 
shown herein in our results. The collateral vascularization is poor if the patient suffers 
from diabetes and end-stage kidney disease, and these patients were shown to benefit 
significantly from direct revascularization (Iida et al. 2013, Shiraki et al. 2015). We found 
similar results in our third study, where direct revascularization was associated with better 
wound healing (HR 1.4, 95%CI 1.5–1.9, p<0.0001) and where hemodialysis together with 
indirect PTA was an independent predictor of major amputation (HR 2.62, 95%CI 1.53–
4.45). 
In order to evaluate the differences between surgical and endovascular revascularization, 
we performed a subanalysis among patients who underwent angiosome-targeted 
revascularization (study II). In this comparison, bypass surgery was associated with a 
better wound healing rate than endovascular revascularization, but the leg salvage rates 
were similar. This comparison included a limited number of patients, and the results can be 
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seen only as preliminary. Also, when comparing the revascularization method in diabetic 
patients (study III), the results show that wound healing was better in bypass surgery, 
independently of the angiosome-orientation, rather than in PTA. 
We can only speculate the possible reasons of the differences between the surgical and 
endovascular method. After bypass, an arterial line with a good diameter perfuses the distal 
part of the lower limb, while after PTA, the size of the arterial line is smaller. Furthermore, 
many patients presented on angiograms with non-significant femoral-popliteal or multiple 
stenoses in revascularized artery; these were usually bypassed in open surgery group. 
Therfore, we can hypothesize that the pressure impact after direct PTA may be smaller 
compared to bypass due to higher resistance in revascularized artery. When non-significant 
stenoses are in series the effect on resistance is roughly cumulative (Flangian et al. 1977, 
Karayanakos et al. 1977). The poor outcome after indirect PTA is easier to understand—in 
these cases, the distal arterial tree is probably very sick and allows only limited 
revascularization, but, in cases of indirect bypass, the pressure still changes more 
dramatically. 
When choosing between surgical and endovascular revascularization, we have to bear in 
mind the completely different levels of invasiveness of the procedures. Especially the 
majority of diabetic patients are elderly fragile women, in whom the aim of as non-
invasive an intervention as possible leads to a shorter hospital stay and quicker 
rehabilitation. Despite the evolution in endovascular technology, long infrapopliteal 
occlusions remain challenging for endovascular therapy due to the high risk of failure and 
a need for repeated revascularization attempts. Failure of endovascular therapy, usually 
after two PTAs, results in a delay of surgical bypass revascularization. Such a delay, 
mainly in diabetics, may lead to poorer leg salvage rates (Noronen et al. 2016). Therefore, 
in cases of long infrapopliteal occlusions where direct EVT is not feasible, the change in 
policy to opt for surgical bypass first seems to bring benefits to the patient, unless the 
patient is too fragile or has other contraindications for the surgical intervention. We must 
bear in mind the different pathophysiology of a diabetic foot and the high tendency for 
infection in diabetic patients. When treating DFUs, revascularizing the foot alone is not 
enough for wound healing as the ischemia does not necessarily play the main role in 
developing the tissue defect. Therefore, cooperation between specialties with adequate 
treatment and follow-up of all factors playing a role in DFU development is needed to 
achieve the best results for diabetic patients. 
Without a doubt, a well-planned, prospective study with a precisely defined wound 
location and size, high-quality angiograms with information on collaterals as well as the 
patency of the pedal arch, and careful wound healing follow-up is needed to confirm the 
usefulness of the angiosome concept in the treatment of CLI and tissue loss. 
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Limitations of the study 
 
A number of limitations may affect the results—all the studies are retrospective, which 
may lead to potential selection bias in terms of the ischemic tissue lesion determination 
according to the angiosome concept. Even though the data has been drawn from our 
prospectively collected database, the identification of the precise ulcer location can be 
difficult in some cases (I–IV). Furthermore, the existence of dual supply to the heel and 
forefoot, resulting in more than one angisomal distribution, may influence the 
determination, because we were unable to distinguish the dominant source artery based on 
preoperative images (I–IV). Also, the determination of the correct angiosome affected by 
ischemia cannot be made based on a DSA or MRA, as information on the microcirculation 
and perfusion of the skin is necessary for a complete determination. The other limitation 
remains in the definition of targeted revascularization in cases where the ulcer spans 
several angiosomes; due to unclear methodology in previous publications, adjustments 
were made in studies II–IV, which could affect the results. Moreover, in some cases, the 
evaluation of angiograms may be problematic due to the poor quality of the images as 
regards limitations in the examined region (I–IV). DSAs were not available in all cases in 
the surgical group, and MRAs were used instead, therefore rendering the information on 
the pedal arteries and the quality of the pedal arch poorer (II–IV).The wound healing time 
in studies II–IV may have been overestimated, because the status was checked 
intermittently and the wound care protocol was not standardized and took place in a 
number of other facilities outside HUCH.  
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CONCLUSION  
Based on this thesis, the following conclusions can be drawn: 
 
1) The angiosome concept is feasible for the majority of patients treated with an 
endovascular approach, although only 24% of the tissue lesions are localized to 
one angiosome only. 
     2) The factors that are associated with worse wound healing time are: a number of 
affected angiosomes of >3, CRP>10 and indirect PTA. 
      3) Surprisingly, there was no significant difference between the patient cohorts in study 
II and III (diabetic patients only). Therefore, observing the angiosome concept in 
the decision-making seems to bring better wound-healing and leg salvage rates, 
especially in endovascular therapy. In bypass surgery, however, the concept seems 
to be of less value, and the artery with the best runoff should be selected as the 
outflow artery. 
     4) It seems that, if the wound spreads over more than one angiosome in the location of 
the forefoot or heel, any angiosome involved in the wound (definition A) can be 
targeted to achieve a better clinical outcome. 
 
In summary, critical limb ischemia presenting as a foot ulcer is a serious impairment of a 
patient’s health status and requires the quick re-establishment of arterial blood supply. The 
tissue lesion affects several angiosomes in the majority of the cases, which seems to be one 
of the main factors delaying wound healing time. Furthermore, in such cases, consensus 
needs to be achieved concerning the accurate definition to standardize the methodology. 
Based on our findings, the angiosome concept plays an important role in endovascular 
treatment, as indirect revascularization leads to the poorest clinical outcomes. 
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